NCT06006013 - Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

December 16, 2025

Study Completion Date

December 16, 2025

Conditions

Locally Advanced Adrenal Cortex CarcinomaAdrenal Cortical CarcinomaStage III Adrenal Cortex CarcinomaStage IV Adrenal Cortex Carcinoma AJCC v8Unresectable Adrenal Cortex Carcinoma

Interventions

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Cabozantinib S-malate

Given PO

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER